Combating Cystic Fibrosis: Computational Studies on CFTR

Hanoch Senderowitz

Department of Chemistry, Bar-Ilan University, Israel

XXV Symposium on Bioinformatics and Computer-Aided Drug Discovery
September 16, 2024

The Cystic Fibrosis Disease

- Most common lethal, inherited disease among people of European descent
- The number of CF patients is estimated at 60,000-165,000 across 94 countries

CF results in pathologies in multiple organs but primarily in the lungs



Median survival age of CF patients



CF is caused by mutations to the CFTR protein

CFTR is an ATP Binding Cassette (ABC) Transporter

- One of the largest and most ancient protein families
  - Membrane proteins
  - Found in prokaryotes and eukaryotes (48 ABC transporters in humans)
  - Harness the power of ATP hydrolysis to mediate substance transport across cell membranes





CFTR is Unique!

CFTR is the only known ion channel in the ABC family

- Historic perspective
  - Gene cloning: 1989 (35 years ago)
  - First low-resolution structure: 2004
  - First published homology model: 2008
  - First cryo-EM structure: 2016
  - First crystal structure: ????



Gating Cycle of CFTR

- CFTR likely has multiple states
- Different states may be clinically relevant



Cant et al. Int J Biochem Cell Biol. 2014;52:15–25

CFTR Mutations

- >2000 CFTR mutations (CF-causing: 719; Non CF-causing: 25)
- All mutations compromise the ability of CFTR to conduct Cl^- ions



Gelfond and Borowitz CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2013;11:333–342

How Do Mutations in CFTR Cause CF?

Treatment Hypothesis

Restoring Cl^- conductance to "normal" levels will ameliorate CF pathologies

Current ~ [# channels] * [open probability]

- **CFTR corrector**: Corrects folding defect and increases number of CFTR channels at cell membrane
- **CFTR potentiator**: Increases open probability of CFTR channels at the membrane
- **Combo therapy:** Does both

Treatment Hypothesis



Available CFTR Modulators

Lumacaftor (corrector)



Elexacaftor (corrector)



Tezacaftor (corrector)



Ivacaftor (potentiator)



Therapy	Luma	Elexa	Teza	Iva	Indication
TriKafta					F508del or 177 specific mutations
Symdeko					F508del/F508del + 154 specific mutations
Orkambi					F508del/F508del
Kalydeco					97 specific mutations

~90% of CF patients are treatable; ~10% are not

Structural Information on NBD1

NBD1 is considered a hot-spot for CF causing mutations

2004: 6 structures, Resolution: 2.2-3.0Å



Today: 36 structures, Resolution: 1.7-3.1Å



CFTR Models



Adapted from: Rahman et al. PLoS One. 2013;8(9):e74574, Corradi et al. J Biol Chem. 2015;290(38):22891–906, Mornon et al. Cell Mol Life Sci. 2015;72:1377–1403

Structural Information on CFTR

20 cryo-EM structures (resolution 2.7-6.9Å) from different species, and representing different conformational states

Inward facing (closed state)

Outward facing (open state)



The Structure of the CFTR Pore



Most structures are excellent starting points for MD simulations

Molecular Dynamic Simulations

- Force field

$$V(r^N) = \sum_{bonds} \frac{k_i}{2}(l_i - l_{i,0})^2 + \sum_{angles} \frac{k_i}{2}(\theta_i - \theta_{i,0})^2$$
$$+ \sum_{torsions} \frac{V_n}{2}(1 + \cos(n\omega - \gamma)) + \sum_{i=1}^{N} \sum_{j=i+1}^{N} \left(4\varepsilon_{ij} \left[\left(\frac{\sigma_{ij}}{r_{ij}} \right)^{12} - \left(\frac{\sigma_{ij}}{r_{ij}} \right)^{6} \right] + \frac{q_i q_j}{4\pi\varepsilon_0 r_{ij}} \right) + \text{cross terms}$$

- Molecular Dynamics

$$v(t) = \frac{dr(t)}{dt}$$

$$F = m \cdot a(t) = m \cdot \frac{dv(t)}{dt}$$

$$\mathbf{r}(t + \delta t) = \mathbf{r}(t) + \delta t \mathbf{v}(t) + \frac{1}{2} \delta t^2 \frac{1}{m} \mathbf{F}(t)$$

$$\mathbf{v}(t + \delta t) = \mathbf{v}(t) + \frac{1}{2} \delta t \frac{1}{m} [\mathbf{F}(t) + \mathbf{F}(t + \delta t)]$$

Replica Exchange MD



Analyzing MD Simulations

"Good" RMSD Plot



"Bad" RMSD Plot



RMSF Plot



Detailed Structure of NBD1



The Dynamics of WT and F508del NBD1



NBD1 in Complex with BIA





Zhenin et al., JCIM **2015,** 55, 2349-2364

Correlating RMSF Profiles with Thermal Stability



RMSF profiles are indicative of thermal instability in NBD1 constructs of hCFTR

Predicting Thermal Stability with FoldX





- Stabilizing mutations benefit from better H-bonds
- Destabilizing mutations suffer from steric clashes

Singh et al., JCHIM **2021**, 61, 1762

MD Simulations at Elevated Temperatures

- WT
- G551D (LSGGQ, +0.22°C): CF-causing
- A559T (ABCα, -10.70°C): CF-causing
- L467P (F1 ATP binding core,-19.30°C): CF-causing
- 6SS (+17.50°C): Stabilizing
- 2PT/M470V (+9.30°C): Stabilizing



Correlate computational predictions with experimental observations
Mechanistic insights

Lublin et al., manuscript in preparation

Study Design

FAST. FLEXIBLE. FREE.
GROMACS



Microsecond long MD simulations at an elevated temperature of 410K (1.8 µs * 6 constructs * 3 replicas) = 32.4 µs

Starting point 2PZE
Protein preparation wizard
Mutate residue
Gromacs 2021.1
AMBER99SB-ILDN FF
Leap-Frog integrator, 2 fs

SCHRÖDINGER.

WT-NBD1
L467P-NBD1
A559T-NBD1
G551D-NBD1
6SS-NBD1
2PT/M470V-NBD1

Minimization
NVT [Berendsen thermostat]
NPT [Parrinello-Rahman, Nose-Hoover thermostat]

Production run

1 Heating from 310K to 410K at a rate of 2ns/1K

2 Maintaining at 410K under NPT conditions for 1.6 µs

RMSD and RMSF







DSSP

A559T-NBD1



WT-NBD1



L467P-NBD1



6SS-NBD1



2PT/M470V-NBD1



G551D-NBD1



Fraction of Native Contacts



Computational metrics are in agreement with experiment (except G551D)

Mechanistic Insights I

Highly destabilized regions in L467P-NBD1 and A559T-NBD1



Stabilizing this region through ligand binding may be beneficial

Mechanistic Insights II: First Points of Disintegration





Computational Studies on full-length CFTR

20 cryo-EM structures (resolution 2.7-6.9Å) from different species, and representing different conformational states



Most structures are excellent starting points for MD simulations

The Q359K / T360K mutation

- Described in Jewish CF patients of Georgian decent
- Results in severe CF phenotype albeit with residual early CFTR function

- No predicted de-stabilization effect
- Pore hindrance
- “electrostatic trap” (?)



Mei-Zahav et al., J Cyst Fibros. 2018 pii: S1569-1993(18)30641-6

MD Simulations of WT-CFTR









Unpublished results

P67L-CFTR

- Rare yet severe mutation
- Molecular consequences poorly characterized
- Correctable by Lumacaftor
- Potentiated by Ivacaftor

- What does it do?



Sabusap et al., J. Biol. Chem., 2021, 296, 100598

P67L-CFTR and P67L/R555K-CFTR









Alostericity

- WT CFTR: Stable H-bond between Y275 (MSD1) and C1355 (NBD2)
- P67L: No such stabilizing interactions





P67L-CFTR: Also a Gating Mutation (?)



WT

Average distance between the NBDs





P67L

Sabusap et al., J. Biol. Chem., 2021, 296, 100598

Conclusions

- CFTR structures are useful
  - Interpretation of data
  - Hypothesis generators
  - Drug design
- More Structures are needed
- Simulations provide insight into the dynamics of WT and mutant CFTR
- For specific mutations, simulations suggest atomic level insights into potential mechanisms of action



Acknowledgements

Michael Zhenin Efrat Noy Ava Xue Netaly Khazanov Luba Simchaev Jacob Spiegel Lior Lublin Malkeet Singh








All Members of the CFTR Consortium

Many Many members of the CF Community

CYSTIC FIBROSIS FOUNDATION THERAPEUTICS

BSF United States – Israel Binational Science Foundation